SLAMF7/CS1 Antibody (YA8564)

Cat. No.: HY-P88880: Data Sheet User Guide for Antibodies
FAQs
Technical Support

SLAMF7/CS1 Antibody (YA8564) is a Mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to SLAMF7/CS1.

For research use only. We do not sell to patients.

Size		Stock
50 μL		Get quote
100 μL		Get quote

* Please select Quantity before adding items.

WB: Western Blot;
IHC-P: Immunohistochemistry-Paraffin;
IHC-F: Immunohistochemistry-Frozen;
ICC/IF: Immunocytochemistry/Immunofluorescence;
IF-Tissue: Immunofluorescence-Tissue;
mIHC: Multiplex Immunohistochemical;
IP: Immunoprecipitation;
ChIP: Chromatin Immunoprecipitation;
FC: Flow Cytometry;
ELISA: Enzyme Linked Immunosorbent Assay

Product Detail
Background
Documentation

Description

SLAMF7/CS1 Antibody (YA8564) is a Mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to SLAMF7/CS1.

Host

Mouse

Clonality

Monoclonal

Molecular Weight

Predicted band size: 37.2 kDa

Species Reactivity

Human

SwissProt ID

Q9NQ25

Immunogen

Full length human recombinant protein of human SLAMF7 produced in HEK293T cell.

Application &
Dilution Ratio

Application	Dilution Ratio
IHC-P IHC-P: Immunohistochemistry-Paraffin	1:150-500
FC FC: Flow Cytometry	1:100

Sensitivity	Endogenous	Purity	Affinity purified
Conjugation	Non-conjugated	Modification	Unmodified
Isotype	IgG2b

Appearance

Liquid

Formulation

Spplied in PBS (pH 7.3) containing 1% BSA, 50% glycerol and 0.02% sodium azide.

Storage & Stability

Stored at -20°C for 1 year. Avoid repeated freeze / thaw cycles.

Shipping

Shipping with blue ice.

Background

Function：Self-ligand receptor of the signaling lymphocytic activation molecule (SLAM) family. SLAM receptors triggered by homo- or heterotypic cell-cell interactions are modulating the activation and differentiation of a wide variety of immune cells and thus are involved in the regulation and interconnection of both innate and adaptive immune response. Activities are controlled by presence or absence of small cytoplasmic adapter proteins, SH2D1A/SAP and/or SH2D1B/EAT-2. Isoform 1 mediates NK cell activation through a SH2D1A-independent extracellular signal-regulated ERK-mediated pathway (PubMed:11698418). Positively regulates NK cell functions by a mechanism dependent on phosphorylated SH2D1B. Downstream signaling implicates PLCG1, PLCG2 and PI3K (PubMed:16339536). In addition to heterotypic NK cells-target cells interactions also homotypic interactions between NK cells may contribute to activation. However, in the absence of SH2D1B, inhibits NK cell function. Also acts inhibitory in T-cells (By similarity). May play a role in lymphocyte adhesion (PubMed:11802771). In LPS-activated monocytes negatively regulates production of pro-inflammatory cytokines (PubMed:23695528)|Isoform 3 does not mediate any NK cell activation

Subcellular Localization：Membrane

Expression：
Tissue_Specificity: Expressed in spleen, lymph node, peripheral blood leukocytes, bone marrow, small intestine, stomach, appendix, lung and trachea. Expression was detected in NK cells, activated B-cells, NK-cell line but not in promyelocytic, B-, or T-cell lines. Expressed in monocytes. Isoform 3 is expressed at much lower level than isoform 1

Isoforms & Post-Translational Modification：Q9NQ25 has 7 isomers: Q9NQ25-1: 37421 Da (predicted); Q9NQ25-2: 25831 Da (predicted); Q9NQ25-3: 37026 Da (predicted); Q9NQ25-4: 17945 Da (predicted); Q9NQ25-5: 32581 Da (predicted); Q9NQ25-6: 22785 Da (predicted); Q9NQ25-7: 21316 Da (predicted).

Subunit：Isoform 1 binds to SH2D1A when its cytoplasmic tail is phosphorylated in the presence of FYN (in vitro); low affinity binding, the physiological relevance of the interaction is questioned

Synonyms

19A; CD319; CRACC; CS1

Documentation

User Guide for Antibodies (1077 KB)